Ea Pharma Co., Ltd.
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 25, 2027The maintenance fee for Heteroarylcarboxylic Acid Ester Derivative (US 9,115,107) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
- 1 fee due Jul 5, 2027The maintenance fee for Heteroarylcarboxylic Acid Ester Derivative (US 9,227,949) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity (US 10,562,898) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Heterocyclic sulfonamide derivative and medicine containing same (US 10,584,116) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Heterocyclic sulfonamide derivative and medicine comprising same (US 10,626,112) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,737,274 | Methods for Producing Phenylalanine Derivatives Having a Quinazolinedione Skeleton and Intermediates for Production Thereof In force · High confidence | In force | High confidence | |
| US 8,609,715 | Heteroarylcarboxylic Acid Ester Derivative In force · High confidence | In force | High confidence | |
| US 8,877,805 | Heteroarylcarboxylic Acid Ester Derivative In force · Medium confidence | In force | Medium confidence | |
| US 9,115,107 | Heteroarylcarboxylic Acid Ester Derivative In force · Medium confidence | In force | Medium confidence | |
| US 9,561,216 | Alkylamine derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 10,166,234 | Pharmaceutical Preparation Comprising Phenylalanine Derivative In force · Medium confidence | In force | Medium confidence | |
| US RE49,569 | Alkylamine derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 9,024,044 | Heteroarylcarboxylic Acid Ester Derivative In force · High confidence | In force | High confidence | |
| US 9,227,949 | Heteroarylcarboxylic Acid Ester Derivative In force · High confidence | In force | High confidence | |
| US 9,655,879 | Heteroarylcarboxylic acid ester derivative In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 19: 8 patents in force now held by others · 59 lapsed for an unpaid fee · 15 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 11 no status recorded